BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20261015T080000
DTEND;TZID=America/New_York:20261015T093000
DTSTAMP:20261006T103616
CREATED:20260924T222022Z
LAST-MODIFIED:20261005T153142Z
UID:3607-1792051200-1792056600@lifescievents.com
SUMMARY:PDS Biotech Virtual KOL Event: PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
DESCRIPTION:Join PDS Biotechnology for a virtual key opinion leader (KOL) event featuring Jonathan M. Hernandez\, M.D. (Investigator\, Surgical Oncology Program\, NCI/CCR) who will join company management to discuss the PDS0301 Phase 2 trials for the treatment of advanced liver-associated cancers with a focus on metastatic colorectal cancer (mCRC). \nThe event will provide an overview of the PDS0301 trials that are in unresectable microsatellite stable (MSS) or mismatch repair-proficient (pMMR) colorectal liver metastases\, constituting the majority of mCRC. PDS0301 is an investigational IL-12 immunocytokine designed using an antibody that binds to necrotic DNA that is found within tumors. PDS0301 specifically targets and delivers the IL-12 into the tumor to promote T cell and natural killer (NK) cell infiltration into the tumor\, as well as localized anti-tumor activation of both T cells and NK cells. \nThe Company anticipates the submission of a registrational Phase 3 clinical trial protocol for PDS0301 in the near future. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/plh7t0s/.
URL:https://lifescievents.com/event/plh7t0s/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/09/Banners-28.png
END:VEVENT
END:VCALENDAR